Impel Pharmaceuticals
$0.04
19
-$0.02-27.27% Wednesday 20:58
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
22MarExpected
Expected EPS
-0.21
Actual EPS
0
Financials
-840.28%Profit Margin
Unprofitable12.65MRevenue
-106.31MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow IMPL. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Show more...
CEO
Michael Hite
Employees
129
Country
United States
ISIN
US45258K1097
WKN
000A3CNH9
Listings
0 Comments
Share your thoughts
FAQ
What is Impel Pharmaceuticals stock price today?▼
The current price of IMPL is $0.04 USD — it has decreased by -27.27% in the past 24 hours. Watch Impel Pharmaceuticals stock price performance more closely on the chart.
What is Impel Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Impel Pharmaceuticals stocks are traded under the ticker IMPL.
What were Impel Pharmaceuticals earnings last quarter?▼
IMPL earnings for the last quarter are 0 USD per share, whereas the estimation was -0.21 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Impel Pharmaceuticals revenue for the last year?▼
Impel Pharmaceuticals revenue for the last year amounts to 12.65M USD.
What is Impel Pharmaceuticals net income for the last year?▼
IMPL net income for the last year is -106.31M USD.
How many employees does Impel Pharmaceuticals have?▼
As of April 15, 2026, the company has 129 employees.
In which sector is Impel Pharmaceuticals located?▼
Impel Pharmaceuticals operates in the Technology sector.
When did Impel Pharmaceuticals complete a stock split?▼
Impel Pharmaceuticals has not had any recent stock splits.
Where is Impel Pharmaceuticals headquartered?▼
Impel Pharmaceuticals is headquartered in Seattle, United States.